Cargando…

Targeting type I interferon (IFN) signalling in patients with RA with a high type I IFN gene signature

Detalles Bibliográficos
Autores principales:	Karonitsch, Thomas, Yeghiazaryan, Lusine, Lackner, Angelika, Brezinsek, Hans Peter, Stamm, Tanja A, König, Franz, Aletaha, Daniel, Smolen, Josef S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Rheumatoid Arthritis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9594563/ https://www.ncbi.nlm.nih.gov/pubmed/36270746 http://dx.doi.org/10.1136/rmdopen-2022-002525

Ejemplares similares

I Would Never Take Preventive Medication! Perspectives and Information Needs of People Who Underwent Predictive Tests for Rheumatoid Arthritis
por: Mosor, Erika, et al.
Publicado: (2020)

Brief Report: Remission Rates With Tofacitinib Treatment in Rheumatoid Arthritis: A Comparison of Various Remission Criteria
por: Smolen, Josef S., et al.
Publicado: (2017)

Baricitinib further enhances disease-modifying effects by uncoupling the link between disease activity and joint structural progression in patients with rheumatoid arthritis
por: Lopez-Romero, Pedro, et al.
Publicado: (2022)

B cell depletion impairs vaccination-induced CD8(+) T cell responses in a type I interferon-dependent manner
por: Graalmann, Theresa, et al.
Publicado: (2021)

Effect of disease duration and prior disease-modifying antirheumatic drug use on treatment outcomes in patients with rheumatoid arthritis
por: Aletaha, Daniel, et al.
Publicado: (2019)

From patients with arthralgia, pre-RA and recently diagnosed RA: what is the current status of understanding RA pathogenesis?
por: Molendijk, Marlieke, et al.
Publicado: (2018)

Infection rates in patients from five rheumatoid arthritis (RA) registries: contextualising an RA clinical trial programme
por: Yamanaka, Hisashi, et al.
Publicado: (2017)

Clinical joint inactivity predicts structural stability in patients with established rheumatoid arthritis
por: Gärtner, M, et al.
Publicado: (2016)

Genetics of RA susceptibility, what comes next?
por: Ding, James, et al.
Publicado: (2015)

Joint involvement in RA starts predominantly in the hands: functional, clinical and imaging studies in clinically suspect arthralgia and during progression to RA
por: Khidir, Sarah J H, et al.
Publicado: (2023)

Time-varying risks of infection in patients as they proceed through the phases of ‘pre-RA’: results from the Scottish Early RA inception cohort
por: Porter, Duncan, et al.
Publicado: (2023)

Interplay between obesity and smoking with regard to RA risk
por: Hedström, Anna Karin, et al.
Publicado: (2019)

Hydroxychloroquine and the risk of respiratory infections among RA patients
por: Kremer, Joel M, et al.
Publicado: (2020)

Predicting achievement of the treatment targets at 6 months from 3-month response levels in rheumatoid arthritis: data from real-life follow-up in the NOR-DMARD study
por: Norvang, Vibeke, et al.
Publicado: (2018)

Interplay between alcohol, smoking and HLA genes in RA aetiology
por: Hedström, Anna Karin, et al.
Publicado: (2019)

JAK inhibition and the holy grail for pain control in early RA
por: Pazmino, Sofia, et al.
Publicado: (2022)

Hand function is already reduced before RA development and reflects subclinical tenosynovitis
por: Krijbolder, Doortje Isabelle, et al.
Publicado: (2023)

Era of biosimilars in rheumatology: reshaping the healthcare environment
por: Smolen, Josef S, et al.
Publicado: (2019)

Variants of genes implicated in type 1 interferon pathway and B-cell activation modulate the EULAR response to rituximab at 24 weeks in rheumatoid arthritis
por: Juge, Pierre-Antoine, et al.
Publicado: (2017)

Tapering and discontinuation of methotrexate in patients with RA treated with TNF inhibitors: data from the DREAM registry
por: Manders, Sofie H M, et al.
Publicado: (2015)

Fully automated joint space width measurement and digital X-ray radiogrammetry in early RA
por: Platten, Michael, et al.
Publicado: (2017)

Difficult-to-treat rheumatoid arthritis (D2T RA): clinical issues at early stages of disease
por: Leon, Leticia, et al.
Publicado: (2023)

Identifying flares in rheumatoid arthritis: reliability and construct validation of the OMERACT RA Flare Core Domain Set
por: Bykerk, Vivian P, et al.
Publicado: (2016)

Effects of alcohol consumption and smoking on risk for RA: results from a Swedish prospective cohort study
por: Hedenstierna, Louise, et al.
Publicado: (2021)

Treatment journey in rheumatoid arthritis with biosimilars: from better access to good disease control through cost savings and prevention of nocebo effects
por: Smolen, Josef S, et al.
Publicado: (2021)

Safety and efficacy of baricitinib in elderly patients with rheumatoid arthritis
por: Fleischmann, Roy, et al.
Publicado: (2017)

Pragmatic randomised controlled trial of very early etanercept and MTX versus MTX with delayed etanercept in RA: the VEDERA trial
por: Emery, Paul, et al.
Publicado: (2020)

Effectiveness of SARS-CoV-2 vaccination in patients with rheumatoid arthritis (RA) on DMARDs: as determined by antibody and T cell responses
por: Saleem, Benazir, et al.
Publicado: (2022)

Efficacy and drug persistence of baricitinib monotherapy is similar to combination therapy in patients with active RA: a prospective observational study
por: Bayat, Sara, et al.
Publicado: (2022)

Increased mortality in patients with RA-associated interstitial lung disease: data from a French administrative healthcare database
por: Juge, Pierre-Antoine, et al.
Publicado: (2023)

Baseline serum levels of cross-linked carboxy-terminal telopeptide of type I collagen predict abatacept treatment response in methotrexate-naive, anticitrullinated protein antibody-positive patients with early rheumatoid arthritis
por: Wu, Chun, et al.
Publicado: (2022)

Value of imaging detected joint inflammation in explaining fatigue in RA at diagnosis and during the disease course: a large MRI study
por: Matthijssen, X M E, et al.
Publicado: (2021)

In vitro evaluation of disease-modifying antirheumatic drugs against rheumatoid arthritis associated pathogens of the oral microflora
por: Kussmann, Manuel, et al.
Publicado: (2021)

Reexamining remission definitions in rheumatoid arthritis: considering the twenty-eight–joint Disease Activity Score, C-reactive protein level and patient global assessment
por: Felson, David, et al.
Publicado: (2021)

Effectiveness of electronic drug monitoring feedback to increase adherence in patients with RA initiating a biological DMARD: a randomised clinical trial
por: Hebing, Renske CF, et al.
Publicado: (2022)

Influence of disease activity on RA treatment choices in countries with restricted access to expensive, innovative drugs: a discrete choice experiment among rheumatologists
por: Hifinger, Monika, et al.
Publicado: (2017)

Postvaccination anti-S IgG levels predict anti-SARS-CoV-2 neutralising activity over 24 weeks in patients with RA
por: Schmiedeberg, Kristin, et al.
Publicado: (2022)

Impact of tocilizumab administered intravenously or subcutaneously on patient-reported quality-of-life outcomes in patients with rheumatoid arthritis
por: Strand, Vibeke, et al.
Publicado: (2018)

Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: efficacy and safety results of a randomised controlled phase III study
por: Feist, Eugen, et al.
Publicado: (2022)

Body mass index and treatment survival in patients with RA starting treatment with TNFα-inhibitors: long-term follow-up in the real-life METEOR registry
por: Bergstra, Sytske Anne, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_5hmud0llsbk5hlig77lp58nnmc